Core Elements of the new GHSS (2022-2030)

Dr ‘Funmi Lesi, Global Hepatitis Programme
Global HIV, Hepatitis and STIs Programmes
World Health Organization HQ, Geneva, Switzerland

https://www.who.int/publications/i/item/9789240028395

Why post 2021 Global Health Sector Strategies?

- Hepatitis remains a high priority for countries
- New epidemiological trend data, including regional variations
- Advances in science, technology and innovation
- Advances in community-based service delivery and differentiated care
- **COVID-19 context**
  - Strengthening of linkages and integration
  - Shifts in donor funding especially for middle-income countries
  - Alignment with WHO GPW13
- **Inclusion of 2025 “mid point” and 2030 targets**
Vision, goals and strategic directions

Impact indicators and targets

Proposed strategic framework:

A common vision

End epidemics and advance universal health coverage, primary health care and health security

Disease goals

End AIDS and the epidemics of viral hepatitis and sexually transmitted infections by 2030

Strategic directions

1. Deliver high-quality, evidence-based, people-centred, services
2. Optimize systems, sectors and partnerships for impact
3. Generate and use data to drive decisions for action
4. Engage empowered communities and civil society
5. Foster innovations for impact

Drivers of progress

- Gender, equity, and human rights
- Financing
- Leadership and partnerships

Shared

Per disease area
New viral hepatitis diagnostics technologies and testing approaches - improve diagnostics technologies & testing approaches for simplified & accurate HBV & HCV inc self testing & self care approaches

Optimized antivirals for hepatitis B and C virus. Support research on optimal doses & formulations of antivirals for HBV & HCV that minimize toxicity, drug-drug interactions and reduce costs; ensure safer antivirals for pregnant and lactating women

New viral hepatitis vaccines. Promote HCV & HEV virus vaccine agenda by promoting investments and visibility in efforts to secure a viable HCV vaccine, inc through strengthened collaboration with R&D partnerships, the private sector and communities.

Hepatitis B virus cure. Promote investments and visibility in efforts to secure a viable HBV cure through strengthened collaboration with R&D partnerships, the private sector and communities.

Partnerships for innovation. Optimize the potential for innovation through market analyses and strengthening research- and development-based partnerships, including strengthened engagement with the private sector.
### Proposed impact indicators and targets for hepatitis

<table>
<thead>
<tr>
<th>Disease area</th>
<th>Impact indicator</th>
<th>Baseline 2020</th>
<th>2025 target</th>
<th>2030 target</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Hepatitis B surface antigen (HBsAg) prevalence among children under 5 years old</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral hepatitis</td>
<td>Number of new hepatitis B infections per year</td>
<td>0.94%</td>
<td>0.5%</td>
<td>0.1%</td>
</tr>
<tr>
<td></td>
<td>Number of new hepatitis C infections per year</td>
<td>1.5 million new cases</td>
<td>850 000 new cases</td>
<td>170 000 new cases</td>
</tr>
<tr>
<td></td>
<td>Number of new hepatitis C infections among persons who inject drugs per year</td>
<td>20 per 100 000</td>
<td>11 per 100 000</td>
<td>2 per 100 000</td>
</tr>
<tr>
<td></td>
<td>Number of deaths due to hepatitis B per year</td>
<td>820 000 deaths</td>
<td>530 000 deaths</td>
<td>310 000 deaths</td>
</tr>
<tr>
<td></td>
<td>Number of deaths due to hepatitis C per year</td>
<td>290 000 deaths</td>
<td>240 000 deaths</td>
<td>140 000 deaths</td>
</tr>
</tbody>
</table>

---
WHO website

Key stages of the strategies’ development process, including reports of the regional and virtual consultation, and the final full draft strategy and table outlining WHO Secretariat response is available online.
New Directions - Updating WHO hepatitis guidelines 2021-2022

**HCV treatment:**
- Simplified service delivery
- Reconciling paediatric and adult DAA regimens
- Re-treatment approaches and regimens

**Testing:** ongoing UNITAID funded portfolio
- Use of PoC viral load
- Reflex viral load
- HCV Self-testing
- Dried Blood spots

**HBV treatment:**
- Simplifying service delivery
- Expanding criteria for treatment (lower APRI score and HBV DNA threshold)
- TAF vs. TDF
- Delta virus testing and treatment

*updated guidelines coming soon*
Thank you